Growth hormone secretagogues: CJC-1295 and Ipamorelin

Two molecular classes on the growth hormone axis

CJC-1295 and Ipamorelin are two synthetic compounds studied in preclinical research on the growth hormone axis. Both compounds act on different receptors within the same signalling axis, making them a frequently referenced research pair in laboratory models.

CJC-1295: a GHRH analogue

CJC-1295 is a synthetic analogue of growth hormone releasing hormone, abbreviated GHRH, the endogenous hypothalamic peptide that acts on the pituitary via the GHRH receptor. At the molecular level, CJC-1295 is studied in research models for its receptor binding and for how structural modifications relative to the native GHRH molecule affect peptide stability.

Ipamorelin: a ghrelin receptor agonist

Ipamorelin belongs to a different molecular class. It is a pentapeptide that acts on the ghrelin receptor, also known as the growth hormone secretagogue receptor, or GHS-R. This receptor is molecularly distinct from the GHRH receptor targeted by CJC-1295. Research models study the selectivity of Ipamorelin for the GHS-R relative to other receptors within the same family.

The DAC distinction and half-life

Within the CJC-1295 research line, a distinction is made between variants with and without a Drug Affinity Complex, abbreviated DAC, a structural modification that in laboratory models is associated with prolonged binding to plasma albumin and, consequently, an extended molecular half-life compared to the non-DAC variant. Research on these two variants focuses on the pharmacokinetic differences at the molecular level, without any claims regarding application.

Why these two are studied as a research pair

Because CJC-1295 and Ipamorelin act on two distinct receptors within the same growth hormone axis, the GHRH receptor versus the GHS-R, they form a complementary pair in research models for mapping the regulation of this axis at the receptor level. This type of research is directed exclusively at molecular and preclinical mechanisms.

• CJC-1295, GHRH analogue, acting on the GHRH receptor
• Ipamorelin, pentapeptide, selective agonist of the ghrelin receptor GHS-R
• DAC variant studied for extended plasma albumin binding versus the non-DAC variant

Laboratory context only

All mechanisms described originate from preclinical and receptor focused research. No dosage, duration of action in humans, or therapeutic application is described. CJC-1295 and Ipamorelin are offered by togopeptide.com exclusively for research purposes.